Use of Immune Checkpoint Inhibitors in Cancer Patients with Pre-Existing Sarcoidosis

Abstract

<b>Aim:</b> To evaluate adverse events in cancer patients with pre-existing sarcoidosis receiving immune checkpoint inhibitors (ICIs). <b>Patients & methods:</b> We retrospectively reviewed cancer patients with sarcoidosis who underwent treatment with ICI to determine frequency of sarcoidosis flares. <b>Results:</b> 32 patients with sarcoidosis received ICIs The median time to ICI initiation was 7 years (range: 1 month to 51 years). One patient (3%) with a 20-year remote history of sarcoidosis developed a clinically symptomatic exacerbation after three doses of atezolizumab, with hilar lymphadenopathy, subcutaneous nodules, arthritis and uveitis. Atezolizumab was discontinued and prednisone initiated. She had a fluctuating course with two additional flares. <b>Conclusion:</b> Frequency of flares in patients with a remote history of sarcoidosis who receive ICIs is low.